What does it take to bring a breakthrough drug to a value-based market? John Kerins, Director at Cain Brothers, a division of KeyBanc Capital Markets Inc., and David Johnson discuss the intensified need for data, collaboration and communication to bring exceptionally costly but desperately needed therapies to market. They hone in on the growing role of medical affairs and contract commercialization services organizations in meeting the needs of all stakeholders for value.
John and Dave also co-authored a detailed article on the topic. Read it here.